IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up

Authors: Schuster, Stephen J., Hale Fowler, Nathan, Dickinson, Michael, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, José Kersten, Marie, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, José Antonio, Chen, Andy I., Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andrés José María, Teshima, Takanori, Patten, Piers E.M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Patten, Pier E.M., Malladi, Ram, Zia, Aiesha, Awasthi, Rakesh, Paule, Ines, Germano, Davide, Ramos, Roberto, Hsu, Pei, Thieblemont, Catherine, z-Lopez, Martin

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S495-S496